公开(公告)号：US09943401B2

公开(公告)日：2018-04-17

申请号：US12384659

申请日：2009-04-06

Applicant: Eugene de Juan, Jr. ,  Cary J. Reich ,  Stephen Boyd ,  Yair Alster ,  David Sierra ,  Hanson S. Gifford ,  Jose D. Alejandro ,  Richard L. Lindstrom ,  K. Angela Macfarlane ,  Douglas Sutton ,  John Anthony Scholl

Inventor： Eugene de Juan, Jr. ,  Cary J. Reich ,  Stephen Boyd ,  Yair Alster ,  David Sierra ,  Hanson S. Gifford ,  Jose D. Alejandro ,  Richard L. Lindstrom ,  K. Angela Macfarlane ,  Douglas Sutton ,  John Anthony Scholl

IPC: A61F2/14 ,  A61F9/00 ,  G02C7/04

CPC classification number: A61F2/142 ,  A61F2/14 ,  A61F9/00 ,  A61F2250/0067 ,  G02C7/047

Abstract: A therapeutic lens for the treatment of an epithelial defect comprises a layer of therapeutic material disposed over the stroma and/or Bowman's membrane to inhibit water flow from the tear liquid to the stroma and/or Bowman's membrane, such that corneal deturgescence can be restored to decrease corneal swelling and light scattering. The layer may cover and protect nerve fibers to decrease pain. The layer may comprise an index of refraction to inhibit light scatter from an anterior surface of the stroma and/or Bowman's membrane. The lens may comprise a curved anterior surface that provides functional vision for the patient when the epithelium regenerates. The layer of therapeutic material can be positioned on the eye in many ways, for example with a spray that is cured to adhere the layer to the exposed surface of the stroma and/or Bowman's membrane.

公开(公告)号：US5002569A

公开(公告)日：1991-03-26

申请号：US529883

申请日：1990-05-29

Applicant: Richard L. Lindstrom

Inventor： Richard L. Lindstrom

IPC: A61F2/16

CPC classification number: A61F2/1613

Abstract: An intraocular lens denoted as a YAG dimpled lens or dimpled YAG lens, which includes a barrier rim and a YAG spacer area in a posterior surface of the lens. The barrier rim is 2-4 mm in longitudinal length and the YAG spacer is 3-4 mm in longitudinal length across the surface diameter of an optic of the intraocular lens. The lens optic can be either plano-convex or bi-convex. A cutout for the dimpled YAG spacer is provided which is either a convave or a substantially rectangular geometrical configuration in the posterior surface of the lens. The YAG spacer can also include a trough or a groove geometrical configuration, such as in the configurations of a Maltese cross, a circular trough or groove, or a circular trough or groove with a Maltese cross therein. The barrier rim is 33% to 80% of the total surface are of the posterior surface of the lens.

Abstract translation: 一种称为YAG凹凸透镜或凹凸YAG透镜的眼内透镜，其包括镜片后表面中的屏障边缘和YAG间隔区域。 屏障边缘在纵向长度上为2-4mm，并且YAG间隔物在纵向长度上穿过眼内透镜的光学元件的表面直径为3-4mm。 透镜光学元件可以是平凸的或双凸的。 提供了用于凹凸的YAG间隔件的切口，其是在镜片的后表面中的手链或基本上矩形的几何构型。 YAG间隔物还可以包括槽或凹槽几何构型，例如在马耳他十字架，圆形槽或凹槽的构造中，或者在其中具有马耳他十字的圆形槽或槽。 屏障边缘是总表面的33％至80％是透镜的后表面。

公开(公告)号：US4959319A

公开(公告)日：1990-09-25

申请号：US311846

申请日：1989-02-17

Applicant: Debra L. Skelnik ,  Richard L. Lindstrom

Inventor： Debra L. Skelnik ,  Richard L. Lindstrom

IPC: C12N5/071

CPC classification number: C12N5/0621

Abstract: A process for establishing functional human corneal tissue consisting of an enhanced contact-inhibited endothelial monolayer derived from isolated human corneal endothelial cells with other integral corneal layers remaining intact. The process is divided into four integral parts.1. Isolation of human corneal endothelial cells from donor corneas.2. Establishment of a human corneal endothelial cell line which involves the establishment of primary cell cultures, proliferation, and continued maintenance and subculturing of these cells in vitro.3. The utilization of long term storage of isolated human corneal endothelial cells at -80.degree. C.4. Utilizing these isolated corneal endothelial cells from the above processes to enhance the corneal endothelial monolayer of human donor corneas to be used for penetrating keratoplasty.Two distinct methods of corneal endothelial enhancement may be utilized. In the first method, isolated human corneal endothelial cells are incorporated into the existing donor monolayer and re-establish a contact-inhibited functional monolayer, with a flattened, hexagonal configuration. In this procedure, the donor corneal endothelium remains intact and is supplemented with additional corneal endothelium. In the second method, isolated human corneal endothelial cells are seeded onto a denuded Descement's membrane and re-establish an intact cellular matrix, and form a contact-inhibited functional endothelial monolayer. In this procedure, the donor corneal endothelium is completely removed and replaced with new endothelial cells.

Abstract translation: 用于建立功能性人角膜组织的方法，其由来自分离的人角膜内皮细胞的增强的接触抑制内皮单层组成，其余整体角膜层保持完整。 该过程分为四个组成部分。 1.从供体角膜分离人角膜内皮细胞。 2.建立人类角膜内皮细胞系，其涉及在体外建立原代细胞培养物，增殖和持续维持和传代培养这些细胞。 3.在-80℃下利用长期保存的孤立人角膜内皮细胞。4.利用上述方法分离的角膜内皮细胞，增强用于穿透角膜移植术的人供体角膜角膜内皮单层。 可以使用两种不同的角膜内皮增强方法。 在第一种方法中，将孤立的人角膜内皮细胞掺入现有的供体单层中，并重新建立具有扁平六边形构型的接触抑制功能单层。 在此过程中，供体角膜内皮保持完整，并补充额外的角膜内皮。 在第二种方法中，将分离的人角膜内皮细胞接种到裸露的Descement膜上并重新建立完整的细胞基质，并形成接触抑制功能内皮单层。 在此过程中，供体角膜内皮被完全去除，并用新的内皮细胞代替。

公开(公告)号：US4725586A

公开(公告)日：1988-02-16

申请号：US836156

申请日：1986-03-04

Applicant: Richard L. Lindstrom ,  Debra Skelnik

Inventor： Richard L. Lindstrom ,  Debra Skelnik

IPC: A61K31/715 ,  A61K9/00 ,  A61K31/70

CPC classification number: A61K9/0048

Abstract: A surgical or irrigation solution which provides the anterior and posterior chamber of the eye with protection during surgical procedures that require irrigation. This irrigation solution is composed of a HEPES buffered Eagle's Minimum Essential Media (MEM) with Earle's Salts, without phenol red, supplemented with mixed isomers of 99% pure, chondroitin sulfate, MEM non-essential amino acids, 2-mercaptoethanol, and sodium pyruvate. Other solutions include a balanced salt solution, chondroitin sulfate, buffers and 2-mercaptoethanol. The solution can also be used in other surgical or medical applications.

Abstract translation: 一种手术或灌洗液，其在需要灌洗的手术过程中提供眼睛的前房和后房保护。 该灌注溶液由具有Earle Salts的HEPES缓冲的Eagle's Minimum Essential Media（MEM），不含酚红，补充99％纯度的混合异构体，硫酸软骨素，MEM非必需氨基酸，2-巯基乙醇和丙酮酸钠 。 其他溶液包括平衡盐溶液，硫酸软骨素，缓冲液和2-巯基乙醇。 该解决方案也可用于其他手术或医疗应用。

公开(公告)号：US10206814B2

公开(公告)日：2019-02-19

申请号：US14989072

申请日：2016-01-06

Applicant: David R. Hardten ,  Richard L. Lindstrom

Inventor： David R. Hardten ,  Richard L. Lindstrom

IPC: A61F9/00

Abstract: A method for delivering fluids, drugs, or medications to a patient's eye, and a system or apparatus for implementing the method, is disclosed. The system and method comprises the use of a corneal sponge to be deposited onto the cornea of the patient's eye while the patient's eyelids are maintained in open positions, and a scleral contact lens is disposed onto the sponge. The scleral lens has an irrigation fluid supply tube fluidically connected thereto for supplying a fluid, drug, or medication to the sponge which is saturated with the fluid, drug, or medication. Once the sponge and lens are inserted onto the corneal region of the eye, the patient's eyelids are closed thereby trapping and maintaining the sponge and lens upon the corneal region of the eye so as to permit the fluid, drug, or medication to be continuously supplied and applied to the corneal region of the eye.

公开(公告)号：US20170189229A1

公开(公告)日：2017-07-06

申请号：US14989072

申请日：2016-01-06

Applicant: DAVID R. HARDTEN ,  RICHARD L. LINDSTROM

Inventor： DAVID R. HARDTEN ,  RICHARD L. LINDSTROM

IPC: A61F9/00

CPC classification number: A61F9/0017

Abstract: A method for delivering fluids, drugs, or medications to a patient's eye, and a system or apparatus for implementing the method, is disclosed. The system and method comprises the use of a corneal sponge to be deposited onto the cornea of the patient's eye while the patient's eyelids are maintained in open positions, and a scleral contact lens is disposed onto the sponge. The scleral lens has an irrigation fluid supply tube fluidically connected thereto for supplying a fluid, drug, or medication to the sponge which is saturated with the fluid, drug, or medication. Once the sponge and lens are inserted onto the corneal region of the eye, the patient's eyelids are closed thereby trapping and maintaining the sponge and lens upon the corneal region of the eye so as to permit the fluid, drug, or medication to be continuously supplied and applied to the corneal region of the eye.

公开(公告)号：US6090141A

公开(公告)日：2000-07-18

申请号：US910734

申请日：1997-08-13

Applicant: Richard L. Lindstrom

Inventor： Richard L. Lindstrom

IPC: A61F2/14

CPC classification number: A61F2/147 ,  A61F2/14

Abstract: An intracorneal lens that is inserted between stromal layer of a cornea of an eye, and provides two distinct regions of focality. The lens includes a central region with a thinner wall and a surrounding region with a thicker wall.

Abstract translation: 插入在眼角膜的基质层之间并且提供两个不同的焦点区域的角内透镜。 透镜包括具有较薄壁的中心区域和具有较厚壁的周围区域。

公开(公告)号：US5628794A

公开(公告)日：1997-05-13

申请号：US613958

申请日：1996-03-08

Applicant: Richard L. Lindstrom

Inventor： Richard L. Lindstrom

IPC: A61F2/14

CPC classification number: A61F2/1613 ,  A61F2/145 ,  A61F2/15 ,  A61F2/1618

Abstract: Hydrogel coated multifocal intraocular implantable lens having an anti-glare edge surrounded by a hydrogel ring having nutrient passage capabilities.

Abstract translation: 具有由具有营养通过能力的水凝胶环包围的防眩光边缘的水凝胶涂覆的多焦点眼内可植入透镜。

公开(公告)号：US5102653A

公开(公告)日：1992-04-07

申请号：US463485

申请日：1990-01-11

Applicant: Debra L. Skelnik ,  Richard L. Lindstrom

Inventor： Debra L. Skelnik ,  Richard L. Lindstrom

IPC: A61K49/00

CPC classification number: A61K49/00 ,  Y10S514/912

Abstract: This is a non-primate vitreal replacement process that quantitates the inflammatory response to viscoelastic agents or solutions. More specifically, the rabbit vitreal replacement process consists of the surgical replacement of a small volume of the central gel vitreous of the rabbit with a viscoelastic agent or solution, and measuring the invasion of white blood cells in the vitreous and anterior chamber at 48 hours post injection. Additional parameters measured are anterior chamber flare, haze and flare in the vitreal chamber, ocular fundus clarity, presence of iris congestion, lens involvement, corneal clarity, conjunctival congestion and conjunctival swelling. In this process, the rabbit is evaluated prior to injection of the viscoelastic agent or solution and 48 hours post injection. Each parameter is evaluated on a scale of 0 to 5. A non-inflammatory sample consists of a mean total score of equal to or less than one or a vitreal cell count less than 50 cells/mm.sup.3. This is an extremely sensitive system for detecting small amounts of inflammatory agents in viscoelastic agents or solutions. The test solution is rated as acceptable for veterinary or human use if a non-inflammatory response is obtained in this process.

Abstract translation: 这是非灵长类玻璃体替代过程，其定量为粘弹剂或溶液的炎症反应。 更具体地，兔子玻璃体替代过程包括用粘弹性剂或溶液手术置换少量兔中心凝胶玻璃体，并在48小时后测量玻璃体和前房中白细胞的侵入 注射。 测量的附加参数是玻璃体腔中的前房耀斑，浑浊和耀斑，眼底清晰度，虹膜充血的存在，镜片参与，角膜清晰度，结膜充血和结膜肿胀。 在该过程中，在注射粘弹剂或溶液之前和注射后48小时评价兔子。 每个参数以0至5的等级进行评估。非炎性样品由等于或小于1的平均总分数或小于50个细胞/ mm 3的玻璃体细胞计数组成。 这是一种非常敏感的系统，用于在粘弹剂或溶液中检测少量的炎症因子。 如果在该过程中获得非炎症反应，则测试溶液被评为兽医或人类可接受的。

公开(公告)号：US4713375A

公开(公告)日：1987-12-15

申请号：US761406

申请日：1985-08-01

Applicant: Richard L. Lindstrom ,  Debra L. Skelnik

Inventor： Richard L. Lindstrom ,  Debra L. Skelnik

IPC: C08L1/00 ,  A61K31/70

CPC classification number: C08L1/00

Abstract: Viscoelastic solution including a buffered solution, 1-8% cellulose gum and 1-8% chondroitin sulfate, pH adjusted to 7.2-7.6 at a osmolality between 200-400 MOSM. The buffered solution can be HEPES buffered minimum essential media (MEM), phosphate buffer system (PBS), balanced salt solution, or TC199.

Abstract translation: 包括缓冲溶液，1-8％纤维素胶和1-8％硫酸软骨素的粘弹性溶液，在200-400MMM之间的重量摩尔渗透压浓度下将pH调节至7.2-7.6。 缓冲溶液可以是HEPES缓冲的最小必需培养基（MEM），磷酸盐缓冲液（PBS），平衡盐溶液或TC199。